Skip Navigation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Bendandi, M.
Right arrow Articles by Zinzani, P. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bendandi, M.
Right arrow Articles by Zinzani, P. L.
Related Collections
Right arrow 2004 - Review Articles
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 15:703-711, 2004
© 2004 European Society for Medical Oncology

Challenging paradigms in lymphoma treatment

M. Bendandi1,*,§, S. A. Pileri2 and P. L. Zinzani3

1 Department of Hematology and Cell Therapy Area, University Clinic, University of Navarra, Pamplona, Spain; 2 Chair of Pathologic Anatomy & Unit of Haematopatology and 3 Lymphoma Unit, Institute of Haematology and Clinical Oncology ‘L. & A. Seràgnoli’, Bologna University, Bologna, Italy

Received 30 April 2003; revised 23 September 2003; accepted 16 December 2003

Key words: lymphoma classification, lymphoma treatment

The first 150 words of the full text of this article appear below.

Introduction

Among the several merits that must be ascribed to the Revised European–American Lymphoma (REAL) classification [1], the most relevant from a therapeutic standpoint is that it has ultimately allowed clinicians all over the world to fully compare the results of clinical trials conducted elsewhere. Therefore, it is not surprising that it was included almost untouched within the current WHO classification of Tumours of Haematopoietic and Lymphoid Tissues [2]. All previous lymphoma classifications had failed in this scope, mainly owing to the different language and concepts used by pathologists and clinicians in different countries to refer to the variegate panorama of lymphoid tumors.

Meanwhile, the continuous effort towards the refinement of lymphoma patients’ prognosis systems has also succeeded in elaborating new and better prognostic indeces, such as the International Prognosis Index (IPI) [3] and, perhaps, the more recent Follicular Lymphoma International Prognostic Index (FLIPI) [. . . [Full Text of this Article]

Hodgkin’s disease

Diffuse large B-cell lymphoma

Mantle cell lymphoma

Follicular lymphoma

Extranodal marginal-zone B-cell lymphoma of MALT-type

Conclusion

Acknowledgements


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?